Baby Formula Giant Writes $385M Check Over a Dirty Plant

Civil enforcement, not criminal prosecution, is how the U.S. most often resets broken food-safety systems—and Abbott’s nearly $385 million False Claims Act resolution over unsanitary infant-formula manufacturing conditions is a case study in how that lever works and why it matters for public health, corporate compliance, and government purchasing.

The Short Version

Abbott agreed to pay nearly $385 million to resolve federal and state False Claims Act allegations tied to unsafe powdered infant-formula manufacturing conditions.
The settlement grows out of a 2022 DOJ complaint and consent decree requiring stringent remediation at Abbott’s Sturgis, Michigan plant.
Regulators prioritized process correction and oversight—classic food-safety practice—over a contested criminal case.
The case underscores how civil tools protect federal nutrition programs when contamination risk undermines regulatory compliance.

What the government alleged and what Abbott is paying to resolve

The Justice Department’s civil case centered on manufacturing practices that failed to meet the Food and Drug Administration’s good manufacturing practice (GMP) standards for infant formula—rules that exist to prevent contamination, including from Cronobacter sakazakii. In 2022, the government filed a complaint and a proposed consent decree in federal court that allowed Abbott to restart production only under court-enforceable conditions: third-party expert oversight, corrective actions, environmental monitoring, and tight verification before release of product from Sturgis, Michigan. Those filings provide the backbone of the civil allegations and the compliance framework that followed.

Against that backdrop, Abbott has now agreed to pay nearly $385 million to settle False Claims Act allegations brought by DOJ and participating states. The theory is straightforward: when a manufacturer sells into federal programs—such as those serving low-income families—while operating outside required safety standards, those invoices can become “false claims.” Civil recoveries in that posture are designed to claw back public funds and deter GMP breaches that jeopardize vulnerable populations.

How civil enforcement resets a plant’s safety system

Consent decrees are the FDA’s workhorse when systemic risk emerges. They require companies to harden sanitation controls, validate kill-steps and environmental monitoring, document preventive controls, and subject the plant to independent oversight before and after resumption of operations. For infant formula—where the consumer is uniquely fragile—these measures go beyond lot-by-lot testing; they are about building a contamination-intolerant system. The Sturgis decree required Abbott to retain outside experts, implement enhanced sampling and corrective action protocols, and seek FDA sign-off before expanding production—all aligned with the statute’s focus on preventing hazards rather than merely detecting them after the fact.

This approach reflects a pragmatic regulatory calculus. Proving product-specific causation in infant illnesses can be difficult, particularly when samples are few or degraded. But regulators do not need a conclusive chain from jar to patient to require a plant to remediate systemic lapses. When environmental findings and sanitation breakdowns show unacceptable risk, FDA and DOJ use civil remedies to force structural fixes quickly—protecting consumers while the evidentiary thicket of causation remains secondary to prevention.

What closed criminally and what continued civilly

Federal authorities ended their criminal probe without charges while pursuing a civil path that recovers public dollars and cements process improvements. That sequencing is not unusual in food-and-drug enforcement, where civil consent decrees and FCA settlements often provide faster, more certain public-health protection than criminal litigation, and where intent standards and proof hurdles can be high. Reporting on the government’s decision emphasized the pivot to civil tools and money recovery tied to federally funded nutrition programs.

Importantly, the 2022 civil complaint and consent decree stand on their own: they detail the plant conditions, mandate remediation, and give the agency inspection leverage. The new settlement layers financial accountability for selling into federal channels while out of compliance. Together, they illustrate the two-track model—process correction first; fiscal deterrence next—that has characterized FDA-DOJ responses to sanitation breakdowns in high-sensitivity products.

Why Cronobacter risk in powdered formula is uniquely unforgiving

Cronobacter sakazakii is an environmental organism that can survive in dry niches and cause severe disease in infants. Powdered formula is not a sterile product; GMPs therefore require rigorous environmental hygiene and controls to minimize risk. Even sporadic environmental positives, if not bracketed by aggressive sanitation and verification, can signal that dust, equipment harborage points, or traffic patterns are not under control. That is why consent decrees in infant formula plants often focus on airflow management, dry cleaning procedures, nonproduct contact surface monitoring, traffic zoning, and hygienic design—mechanisms that attack the routes by which a hardy dry-environment bacterium can persist.

The policy implication is clear: the system is the safety. Finished-product testing is a last line of defense; robust environmental control is the first. When that first line fails, regulators move to reset the system with court-enforced obligations—precisely what occurred here.

Abbott agrees to settlement over closure of largest baby formula plant in the US https://t.co/w1WY0RhtkI #Abbott #BabyFormula #InfantHealth #ChildNutrition #FDA

— Gbobal Buzz Daily (@JayaK38648) September 14, 2026

The False Claims Act as a nutrition-program safeguard

The FCA is not just a healthcare fraud tool; it polices quality-compliance representations embedded in claims to federally funded programs. If a manufacturer certifies compliance while operating outside GMPs, the government can recover payments and impose penalties. In food, that can be decisive where the public buyer is WIC or related programs serving infants and children. By attaching monetary consequences to sanitation failures, the FCA aligns corporate incentives with the government’s zero-tolerance posture for systemic contamination risk in products intended for the most vulnerable.

What this means going forward—for manufacturers and for parents

For manufacturers, the lesson is unambiguous: treat environmental monitoring and hygienic design as core financial controls, not regulatory overhead. The cost of noncompliance now reliably includes court supervision, production throttles, and nine-figure settlements that dwarf the expense of preventive engineering. For boards, this migrates GMP oversight from plant-level hygiene to enterprise risk: audit committees should insist on near-real-time environmental metrics, red-team reviews of sanitary design, and escalation protocols that reach the board when action thresholds are crossed.

For parents and caregivers, the practical takeaway is different. The U.S. framework—inspection, recall authority, consent decrees, and targeted civil recoveries—aims to prevent recurrence by forcing systemic fixes before large-scale distribution resumes. When regulators let a plant restart under a decree, it is because new controls, sampling intensity, and expert oversight have moved the risk profile back within acceptable limits. That does not eliminate risk inherent to any non-sterile powdered product, but it does re-anchor safety to validated processes rather than assurances alone.

How this case fits the broader pattern of food-safety enforcement

Abbott’s resolution sits alongside a familiar pattern: when sanitation systems fail in high-risk categories, the government compels remediation through injunctions and consent decrees, then uses civil settlements to claw back public funds and reinforce deterrence. In recent years, FDA and DOJ have repeatedly favored this model to restore compliance faster and with tighter ongoing oversight than a criminal trial would deliver—particularly when the central issue is systemic risk rather than clear-cut, product-specific causation. The result is a practical equilibrium: rapid risk reduction, meaningful financial accountability, and a regulatory baseline that other manufacturers would be wise to heed.